China This week’s China healthcare highlights from PharmaBoardroom content partner Selesta include Simcere securing Greater China rights to RB0026, Immunofoco resubmitting its Hong Kong IPO, Fulcrum merging with Slate Medicines, Henlius signing a US$ 322M deal with Sandoz, and KeyMed proposing a STAR Market listing. Clinical highlights feature Sunshine Guojian’s NMPA…
China Chinese drugmakers are increasingly looking past the NMPA toward approvals in the EU, US, and Australia. Daphne Smyth of Veristat has watched this shift from the front row, guiding sponsors through the data gaps, bridging studies, and regulatory quirks that stand between a China-developed drug and a Western marketing authorisation.…
Global Five conferences, five continents’ worth of anxiety, one unmistakable pattern: the global pharma industry is being reshaped faster than it can keep up. From Philadelphia to Geneva, Istanbul to Chicago to London, the Shawview Consulting team found the same threads running through every panel and corridor conversation — AI and…
APAC For two decades the case for running a clinical trial in Asia was essentially arithmetic: the same study, for less money. That argument has not gone away, but it is no longer the one APAC’s own CRO leaders make. Asia Pacific is now the only region in the world where…
China Our goal is to generate rigorous clinical data demonstrating that these therapies can deliver meaningful and lasting benefits for patients For decades, neurological diseases such as Parkinson’s disease, spinal cord injury, MSA and ALS have remained among the most difficult conditions to treat, with available therapies largely focused on managing…
China China has built one of the world’s most advanced digital health ecosystems — large, fast-moving, and integrated across hospitals, internet platforms, insurers, pharmaceutical companies, and regulators. AI is now embedded across the entire value chain: drug discovery, clinical trial management, medical imaging, patient triage, and hospital workflows. Insilico Medicine is…
China As the global clinical development landscape becomes more fragmented and competitive, biotechs increasingly need partners that can help them navigate regulatory complexity, identify the right trial locations, and generate meaningful data quickly. In this context, Harvest Integrated Research Organization has been expanding its international footprint while positioning itself as a…
China Dr Long Jiang is the CEO of GCP ClinPlus, a Chinese CRO with operations in New Jersey. A former cardiovascular surgeon at Peking University People’s Hospital, he shifted into clinical research after a fellowship at Duke Clinical Research Institute, and later also served as a partner in a private equity firm focusing…
China After six years leading the French Healthcare Alliance China, Olivier Dessajan has watched the Franco-Chinese healthcare relationship transform beyond recognition; from a one-way flow of products and partnerships into something far more reciprocal. In conversation at the Asia Summit on Global Health 2026 in Hong Kong, Dessajan reflects on what…
China Belief BioMed’s Co-Founder and CEO, Dr Jane Zheng, sets out an ambition to move gene therapy beyond scientific promise and into a scalable, globally accessible treatment model. Built on an AAV platform and supported by integrated manufacturing, the company is advancing from its haemophilia B proof of concept into broader…
Asia-Pacific Translating scientific breakthroughs into products that genuinely impact patients is more challenging than it has ever been. Only ten percent of drugs that enter clinical trials ever make it all the way to patients, meaning that much of the USD 250 billion spent on pharma R&D every year goes towards…
China Biosion has built a distinctive position within the new generation of Chinese biotech companies pursuing more capital-efficient, globally connected growth. Built around antibody innovation, early value creation, and selective partnering, the company has positioned itself to compete internationally without absorbing the full financial impact of late-stage development alone. Founder Mingjiu…
See our Cookie Privacy Policy Here
